Wall Street brokerages expect that AveXis Inc (NASDAQ:AVXS) will report earnings per share (EPS) of ($1.51) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for AveXis’ earnings. The lowest EPS estimate is ($1.91) and the highest is ($0.69). AveXis reported earnings per share of ($0.92) during the same quarter last year, which suggests a negative year over year growth rate of 64.1%. The business is expected to issue its next earnings report on Thursday, March 15th.
On average, analysts expect that AveXis will report full-year earnings of ($6.23) per share for the current year, with EPS estimates ranging from ($6.61) to ($5.36). For the next year, analysts anticipate that the business will post earnings of ($5.89) per share, with EPS estimates ranging from ($7.33) to ($2.90). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for AveXis.
AveXis (NASDAQ:AVXS) last released its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.04). During the same period last year, the company earned ($0.87) EPS.
Several research analysts recently weighed in on AVXS shares. Jefferies Group lifted their price objective on shares of AveXis to $118.00 and gave the stock a “buy” rating in a research note on Thursday, October 12th. Goldman Sachs Group reaffirmed a “buy” rating and issued a $130.00 price target on shares of AveXis in a research note on Friday, October 6th. UBS Group reaffirmed a “buy” rating and issued a $122.00 price target (up previously from $95.00) on shares of AveXis in a research note on Tuesday, October 3rd. Zacks Investment Research raised shares of AveXis from a “hold” rating to a “buy” rating and set a $112.00 price target on the stock in a research note on Tuesday, October 24th. Finally, Bank of America cut their price target on shares of AveXis from $115.00 to $112.00 and set a “buy” rating on the stock in a research note on Friday, November 10th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have issued a buy rating to the company. AveXis currently has an average rating of “Buy” and an average target price of $113.89.
AveXis (AVXS) traded down $4.07 during trading on Friday, reaching $120.48. 341,442 shares of the company traded hands, compared to its average volume of 773,579. AveXis has a twelve month low of $52.40 and a twelve month high of $128.00. The company has a market cap of $4,414.96, a price-to-earnings ratio of -22.32 and a beta of 2.46.
In other news, VP James J. Litalien sold 5,000 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $106.52, for a total value of $532,600.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $94.77, for a total transaction of $168,690.60. Following the completion of the sale, the vice president now directly owns 1,780 shares in the company, valued at approximately $168,690.60. The disclosure for this sale can be found here. In the last three months, insiders sold 40,560 shares of company stock worth $4,152,752. 18.60% of the stock is currently owned by insiders.
Several hedge funds have recently made changes to their positions in the company. Amalgamated Bank lifted its position in shares of AveXis by 19.6% in the third quarter. Amalgamated Bank now owns 3,187 shares of the company’s stock worth $308,000 after purchasing an additional 523 shares in the last quarter. Parametric Portfolio Associates LLC lifted its position in shares of AveXis by 2.9% in the second quarter. Parametric Portfolio Associates LLC now owns 20,943 shares of the company’s stock worth $1,721,000 after purchasing an additional 598 shares in the last quarter. Jennison Associates LLC lifted its position in shares of AveXis by 0.5% in the fourth quarter. Jennison Associates LLC now owns 185,094 shares of the company’s stock worth $20,484,000 after purchasing an additional 883 shares in the last quarter. ProShare Advisors LLC lifted its position in shares of AveXis by 6.4% in the second quarter. ProShare Advisors LLC now owns 16,427 shares of the company’s stock worth $1,350,000 after purchasing an additional 985 shares in the last quarter. Finally, Strs Ohio bought a new stake in shares of AveXis in the third quarter worth $116,000. 82.77% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “-$1.51 EPS Expected for AveXis Inc (AVXS) This Quarter” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/31/1-51-eps-expected-for-avexis-inc-avxs-this-quarter.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Get a free copy of the Zacks research report on AveXis (AVXS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.